Related Experiment Videos
[Reperfusion therapy in acute myocardial infarction today: thrombolysis, balloon angioplasty and stenting]
1Department of Cardiology, Tokyo Metropolitan Hiroo General Hospital.
Insights
Promptly restoring coronary flow is key for acute myocardial infarction survival. While thrombolytic therapy and primary angioplasty have roles, coronary stenting shows promise, though further research is needed.
Area of Science:
- Cardiology
- Interventional Cardiology
Context:
- Acute myocardial infarction (AMI) management focuses on rapid reperfusion.
- Thrombolytic therapy has been the standard of care, with advancements like accelerated tissue plasminogen activator (t-PA) offering potential benefits.
- Primary percutaneous transluminal coronary angioplasty (PTCA) is effective in experienced hands, especially in high-volume centers.
Purpose:
- To compare the efficacy of different reperfusion strategies in acute myocardial infarction.
- To evaluate the role of primary angioplasty versus thrombolytic therapy.
- To assess the emerging evidence for coronary stenting in AMI.
Summary:
- Prompt coronary flow restoration is crucial for AMI outcomes.
- Primary angioplasty mortality varies significantly with hospital volume, similar to thrombolysis with accelerated t-PA in low-volume settings.
- Coronary stenting appears superior to balloon angioplasty and thrombolysis for suitable lesions, but requires further comparative studies.
Impact:
- Highlights the importance of hospital volume and operator experience in primary angioplasty outcomes.
- Suggests that a strategy of thrombolysis with subsequent angioplasty for recurrent ischemia may be as effective as primary angioplasty.
- Indicates a potential shift towards coronary stenting as a preferred reperfusion strategy, pending further evidence.
Abstract:
Prompt restoration of coronary flow is the principal mechanism by which reperfusion therapy improves survival and other clinical outcomes in patients with acute myocardial infarction. Thrombolytic therapy has been the standard for care over the past decade. The use of accelerated administration of tissue plasminogen activator (t-PA) and modified or mutant t-PA which can be administered with a single bolus intravenous injection might bring further benefits. Primary balloon angioplasty (percutaneous transluminal coronary angioplasty: PTCA) is safe and effective when it can be performed quickly by experienced operators, resulting in better coronary flow and short-term survival rates than are obtained with thrombolytic therapy. However, several studies reporting data from more than 5,000 patients, of whom many were treated in low-volume local hospitals showed mortality with primary angioplasty was substantially higher than that reported from high-volume medical centers, and similar to that observed with thrombolysis with accelerated t-PA. The strategy of rapid administration of thrombolytic therapy and subsequent angioplasty only for recurrent ischemia seems to be as effective as primary angioplasty. Recently several reports have indicated that coronary stenting, when performed for suitable lesions and with good technique by experienced operators, is superior to the results obtained with balloon angioplasty and thrombolysis. However, further studies are required to establish the efficacy of primary stenting compared to PTCA.